Shenzhen Weiguang Biological Products Co Ltd

The company maintains a strong liquidity position, with a current ratio of 2.37 and a price-to-book ratio of 2.42, indicating a relatively high asset base relative to equity. Free cash flow of 112.99 million CNY supports operational flexibility, though capital expenditures were negative at -169.69 million CNY, suggesting asset disposals or reduced investment. Profitability metrics show a return on equity of 10.21% and return on assets of 6.59%, both below the median for the Pharmaceuticals & Medical Research sector, which typically exceeds 12% ROE and 8% ROA. Gross profit of 498.61 million CNY represents 39.36% of revenue, but operating income of 283.94 million CNY reflects a 22.42% margin, which is in line with industry norms. The company operates in a single disclosed segment focused on blood products and property leasing, with all revenue derived from the domestic market. This geographic concentration introduces regulatory and demand-side risks, particularly in a sector subject to stringent government oversight. Recent financial performance shows a 1.09 CNY EPS, slightly above the mean estimate of 1.03 CNY, and revenue of 1.27 billion CNY, exceeding the mean estimate of 1.25 billion CNY. Analysts project modest growth, with a 1.4% increase in revenue and a 3.7% increase in EPS expected in the next fiscal year. Risk factors include a medium liquidity rating and a debt-to-equity ratio of 0.35, which is relatively low but could increase with future financing needs. The company has a low dilution risk, with no near-term pressure from share issuance, and no recent ATM or shelf registration disclosures. Recent filings and transcripts highlight the company’s focus on maintaining production capacity and navigating regulatory changes in the blood products sector. No major legal or operational risks were disclosed in the latest 10-K equivalent filing.